Long-Term Data Boost MCO-010
Four-year RESTORE results will shed new light on the durability of Nanoscope’s mutation-agnostic optogenetic therapy
-
1
Nanoscope Therapeutics will present four-year follow-up data from the MCO-010 program at the Retina Society meeting in September 2026.
-
2
MCO-010, branded as MOGENRY, is a one-time intravitreal gene therapy for retinal degeneration due to photoreceptor loss.
-
3
Patients treated with MCO-010 have maintained gains in visual acuity four years post-treatment, according to preliminary data.
-
4
MCO-010 is mutation agnostic and does not require genetic testing, differentiating it from other gene therapies.
-
5
Nanoscope's Biologics License Application for MOGENRY has been accepted by the FDA, moving it closer to regulatory review.
